Clinical trial
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated…
NCT00061633 · Cumberland Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00061633 |
|---|---|
| Title | Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) |
| Official title | A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) |
| Acronym | FAST |
| Lead sponsor | Cumberland Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections |
| Intervention type | Drug |
| Interventions | Telavancin, Vancomycin or antistaphylococcal penicillin |
| Enrollment | 169 |
| Start date | Jun 1, 2003 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Jun 2, 2003 |
| Last update posted | Jan 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: